PCI Pharma Services (PCI) has installed its latest comprehensive Serialization system at its manufacturing 'Center of Excellence' in Tredegar.

The move demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.

The site in Tredegar already offers excellence in potent manufacturing services for customers globally, and this new Serialization technology further strengthens its comprehensive offering.

This investment in the Tredegar facility is part of a significant global initiative to develop the Serialization services across PCI’s global network, which will ultimately exceed more than 90 lines.

Jim Neville, director of operations, Tredegar, said: “This is an important addition to the site’s capabilities. Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD.”

PCI has been actively Serializing commercial products for the US, European and international markets for the past six years, and this investment in the Tredegar capabilities continues to demonstrate PCI’s market-leading position. The integrated technology strategy enables operators in all PCI’s global locations to operate the same graphical user interface, providing a seamless global service.